A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19
暂无分享,去创建一个
[1] K. Iwata,et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study , 2020, Clinical Epidemiology and Global Health.
[2] J. V. Van Eyk,et al. BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers. , 2020, The Journal of clinical investigation.
[3] É. A. Silveira,et al. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.
[4] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[5] R. Baric,et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.
[6] M. Netea,et al. Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly , 2020, Cell.
[7] T. Vekov,et al. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2 , 2020, Biomedicine & Pharmacotherapy.
[8] W. Deng,et al. Advances in research on ACE2 as a receptor for 2019-nCoV , 2020, Cellular and Molecular Life Sciences.
[9] S. El-Kafrawy,et al. Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants , 2020, International Journal of Infectious Diseases.
[10] Caitlin E. Anderson,et al. SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents , 2020, Analytical chemistry.
[11] A. Sahoo,et al. Ivermectin: potential candidate for the treatment of Covid 19 , 2020, The Brazilian Journal of Infectious Diseases.
[12] Anoop Misra,et al. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[13] A. Aouba,et al. Anakinra for patients with COVID-19 , 2020, The Lancet Rheumatology.
[14] M. Massari,et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.
[15] P. Lotti,et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study , 2020, The Journal of Infection.
[16] A. Hess,et al. Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest , 2020, medRxiv.
[17] M. Al-Jaghbeer,et al. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study , 2020, EClinicalMedicine.
[18] A. Ranade,et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19) , 2020, Postgraduate Medical Journal.
[19] F. Palumbo,et al. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia , 2020, Journal of Vascular Surgery: Venous and Lymphatic Disorders.
[20] C. S. Kow,et al. Use of low-molecular-weight heparin in COVID-19 patients , 2020, Journal of Vascular Surgery: Venous and Lymphatic Disorders.
[21] Martina Capuzzo,et al. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays , 2020, Reproductive BioMedicine Online.
[22] Marlin Touma. COVID-19: molecular diagnostics overview , 2020, Journal of Molecular Medicine.
[23] Suchi Goel,et al. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials , 2020, Journal of Biosciences.
[24] Reza Gharebaghi MD MPH FAAO PhDc,et al. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen , 2020, The Journal of Antibiotics.
[25] L. Ren,et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[26] S. Kumar,et al. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy , 2020, The American Journal of Emergency Medicine.
[27] T. Burki. Testing for COVID-19 , 2020, The Lancet Respiratory Medicine.
[28] Adewale Owa,et al. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? , 2020, Journal of Microbiology, Immunology and Infection.
[29] J. Kim,et al. Immunogenicity of a DNA vaccine candidate for COVID-19 , 2020, Nature Communications.
[30] E. Coomes,et al. Favipiravir, an antiviral for COVID-19? , 2020, The Journal of antimicrobial chemotherapy.
[31] E. Wood,et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. , 2020, The Cochrane database of systematic reviews.
[32] Anoop Misra,et al. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[33] Renyi Wu,et al. An Update on Current Therapeutic Drugs Treating COVID-19 , 2020, Current Pharmacology Reports.
[34] G. Costantino,et al. Use of anakinra in severe COVID-19: A case report , 2020, International Journal of Infectious Diseases.
[35] C. Godugu,et al. The current understanding and potential therapeutic options to combat COVID-19 , 2020, Life Sciences.
[36] Alla Turshudzhyan. Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy , 2020, Cureus.
[37] W. Simonson. Vitamin C and coronavirus , 2020, Geriatric Nursing.
[38] G. Catho,et al. COVID-19: don't neglect antimicrobial stewardship principles! , 2020, Clinical Microbiology and Infection.
[39] Hongjun Li,et al. Clinical and imaging features of COVID-19 , 2020, Radiology of Infectious Diseases.
[40] Ssang-Goo Cho,et al. COVID-19: an update on diagnostic and therapeutic approaches , 2020, BMB reports.
[41] Shubing Zhang,et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2 , 2020, European Journal of Clinical Microbiology & Infectious Diseases.
[42] Keshav Rajarshi,et al. Combating COVID-19 with mesenchymal stem cell therapy , 2020, Biotechnology Reports.
[43] E. Nicastri,et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact , 2020, Journal of Infection.
[44] A. Boretti,et al. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome , 2020, PharmaNutrition.
[45] T. A. Abd El-Aziz,et al. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status , 2020, Infection, Genetics and Evolution.
[46] Dena Goffman,et al. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery , 2020, The New England journal of medicine.
[47] A. Ardeshirylajimi,et al. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future , 2020, Stem Cell Reviews and Reports.
[48] B. Liang,et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis , 2020, Journal of Infection.
[49] Shinji Makino,et al. An Infectious cDNA Clone of SARS-CoV-2 , 2020, Cell Host & Microbe.
[50] N. Moore. Chloroquine for COVID-19 Infection , 2020, Drug Safety.
[51] Y. Wen,et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.
[52] M. Day. Covid-19: four fifths of cases are asymptomatic, China figures indicate , 2020, BMJ.
[53] P. Vollmar,et al. Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.
[54] Chengliang Zhu,et al. The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis , 2020, medRxiv.
[55] T. West,et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.
[56] Heng Li,et al. Coronavirus disease 2019 (COVID-19): current status and future perspectives , 2020, International Journal of Antimicrobial Agents.
[57] Anoop Misra,et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[58] Wu Zhong,et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.
[59] E. Holmes,et al. The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.
[60] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[61] W. Tang,et al. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. , 2020, European review for medical and pharmacological sciences.
[62] Feng-hua Chen,et al. Blood transfusion during the COVID-19 outbreak. , 2020, Blood transfusion = Trasfusione del sangue.
[63] G. Chowell,et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[64] Shaoqiang Li,et al. Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis , 2020, Journal of medical virology.
[65] M. Müller,et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform , 2020, Nature.
[66] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[67] Malik Peiris,et al. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia , 2020, Clinical chemistry.
[68] M. Ciccozzi,et al. The 2019‐new coronavirus epidemic: Evidence for virus evolution , 2020, bioRxiv.
[69] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[70] Michael J. Loeffelholz,et al. Laboratory diagnosis of emerging human coronavirus infections – the state of the art , 2020, Emerging microbes & infections.
[71] Chuan Qin,et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight , 2019, Viruses.
[72] A. Khojasteh,et al. The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review. , 2019, Current stem cell research & therapy.
[73] I. Sola,et al. Molecular Basis of Coronavirus Virulence and Vaccine Development , 2016, Advances in Virus Research.
[74] Jing Xie,et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.
[75] K. Singh,et al. The clinical development process for a novel preventive vaccine: An overview , 2016, Journal of postgraduate medicine.
[76] W. Lim,et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.
[77] H. Fausther-Bovendo,et al. Pre-existing immunity against Ad vectors , 2014, Human vaccines & immunotherapeutics.
[78] Antonio Pérez,et al. Glucocorticoid‐induced hyperglycemia (糖皮质激素诱导的高血糖) , 2014, Journal of diabetes.
[79] N. Marwaha,et al. Nucleic acid testing-benefits and constraints , 2014, Asian journal of transfusion science.
[80] K. Bojang,et al. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity , 2012, PloS one.
[81] Y. Takashima,et al. Artificial molecular clamp: a novel device for synthetic polymerases. , 2011, Angewandte Chemie.
[82] Larry J. Anderson,et al. Real-Time Reverse Transcription–Polymerase Chain Reaction Assay for SARS-associated Coronavirus , 2004, Emerging infectious diseases.
[83] H. Hemilä. Vitamin C and SARS coronavirus , 2003, The Journal of antimicrobial chemotherapy.